Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse

Posttransplantation, glasdegib maintenance therapy in patients at high risk for relapse did not meaningfully reduce relapse incidence. Use of glasdegib in the posttransplantation setting was complicated by adverse events requiring drug holds and occasional discontinuation.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Kent, Andrew, Vasu, Sumithira, Schatz, Derek, Monson, Natalie, Devine, Steven, Smith, Clayton, Gutman, Jonathan A., Pollyea, Daniel A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Stimulus Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362348/
https://ncbi.nlm.nih.gov/pubmed/32634235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001991
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados